GM Canada Workers Approve C$1.1 Billion Investment Deal 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Street Poller Media and The Boom of the Street Interview Ad Industry 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Add as a preferred source on Google
VANCOUVER, British Columbia, March 31, 2018 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today recognizes World Lipodystrophy Day.
Chief Operating Officer Jeff Hackman said, "We are honored to join together with the patient community in support of World Lipodystrophy Day, with a goal of increasing awareness of this serious rare disease. Awareness and education are important initiatives which help recognition and diagnosis of the disease.”
Lipodystrophy is a group of rare diseases characterized by a lack of fat tissue. In some patients, it is genetic, and in others it may be acquired. It can be characterized by a widespread lack of fat tissue under the skin (generalized lipodystrophy) or limited lack of fat tissue (partial lipodystrophy). This loss of fat tissue causes a deficit in the hormone leptin, leading to some severe metabolic complications.
“We are passionate about providing support for lipodystrophy patients and their caregivers, and we advocate tirelessly to increase understanding of the disease and further research into lipodystrophy. World Lipodystrophy Day is an important initiative that increases public awareness to help us achieve these goals on behalf of patients living with this serious and often unknown disease,” said Andra Stratton, president and co-founder of Lipodystrophy United.
“The challenges that patients living with lipodystrophy and their families face are significant. World Lipodystrophy Day helps us to raise awareness and understanding so that we can improve diagnosis and care for those affected by this rare disease globally,” said Naca Eulalia Perez de Tudela Cánovas, president and founder of the international organization Association of Families Affected by Lipodystrophies in Spain, Europe & Latin America.
To learn more about lipodystrophy, visit www.lipodystrophyunited.org, www.aelip.es, or www.lipodystrophy.co.uk.
CONTACT:
Novelion Therapeutics Inc.
Amanda Murphy
Director, Investor Relations & Corporate Communications
857-242-5024
